Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Trudy Kiah

Physician Assistant Ogdensburg, NY Physician Assistant

NPI 1083789515 CMS profile 10716381

921 State St, Ogdensburg, NY 13669

Open in the dashboard

General payments

$6,349

357 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trudy Kiah of Ogdensburg, NY is reported in the CMS Open Payments database as having received $6,349 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,339 66
2024 General $1,067 52
2023 General $1,122 64
2022 General $1,116 68
2021 General $1,706 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trudy Kiah
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Trudy Kiah were reported at $1,339. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Trudy Kiah Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,706 $132 $37–$438 $132
2022 $1,116 $155 $48–$522 $149
2023 $1,122 $167 $52–$557 $160
2024 $1,067 $178 $55–$600 $164
2025 $1,339 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,571 67 payments
  2. Novo Nordisk Inc $1,039 67 payments
  3. Lilly USA, LLC $544 36 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $395 19 payments
  5. GlaxoSmithKline, LLC. $387 24 payments
  6. Pfizer Inc. $305 22 payments
  7. AbbVie, Inc. $212 10 payments
  8. Merck Sharp & Dohme Corporation $194 13 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $175 13 payments
  10. Janssen Pharmaceuticals, Inc $172 9 payments
  11. Other $1,355 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,349 357 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,027 35 payments
  2. BREZTRI $729 17 payments
  3. AIRSUPRA $662 20 payments
  4. RYBELSUS $530 31 payments
  5. Ozempic $391 28 payments
  6. Wegovy $298 18 payments
  7. NURTEC ODT $230 16 payments
  8. TRELEGY ELLIPTA $217 15 payments
  9. JARDIANCE $217 15 payments
  10. MOUNJARO $217 13 payments
  11. Other $4,267 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

7,374

Median for Physician Assistant: 241

Drug cost

$875,971

Median for Physician Assistant: $4,110

Branded share of claims

22.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 89 $133,979
Farxiga Dapagliflozin Propanediol Brand 87 $118,889
Eliquis Apixaban Brand 92 $92,681
Mounjaro Tirzepatide Brand 33 $56,823
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $52,622
Xarelto Rivaroxaban Brand 42 $45,745
Jardiance Empagliflozin Brand 40 $36,390
Trulicity Dulaglutide Brand 19 $30,724
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $29,767
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 22 $23,729

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$5,665

Of which drugs: $891

Medicare patients

77

Average age 74

Services billed

234

51 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 38%
Diabetes 36%
Ischemic heart disease 29%
Depression 22%
Heart failure 19%
Chronic kidney disease 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $182
$182 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $173
$173 87 —
Wegovy
  • Novo Nordisk Inc $106
$106 — —
JARDIANCE
  • Lilly USA, LLC $79
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
$105 40 —
Nayzilam
  • UCB, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record